Investor News

Dear Investor,

2017 was quite a  dynamic and important year for TOPADUR and 2018 will bring even more opportunties due to the fact that we are in transition from a pre-clinical to a clinical stage Company. Furthermore 2018 will most certainly also be a good time for market and investment  reflection on your side and to raise your thoughts with regard to the investment environment in general and particularly in the biotechnology sector in Switzerland and hopefully an investment in TOPADUR in the near future.

 

CAPITAL RAISING ROUNDS

Closing of our «Serie B» Fund Raising round took place in September 2017 and our motivated team is now preparing for “Series C” Fund Raising round which will take place in 2018.

 

BIOTECHNOLOGY INVESTMENTS IN SWITZERLAND

A short market review about the very interesting BIOTECHNOLOGY SECTOR in SWITZERLAND and the Investors Outlook for 2018 and above do present you additionally the dynamic development in our small Swiss Biotechnology Scene, which most certainly will also further enhance TOPADUR’s offering to be a lucrative Investment Option for you in the near future.

For more INFORMATION
CLICK HERE

 

WHY SHOULD YOU INVEST IN TOPADUR ?

What exactly are the key arguments to be raised to actually invest in TOPADUR and what makes us an added value provider and important asset for your private equity portfolio ?

Find out more
CLICK HERE

 

CONTACT

The interested investors will obtain more information via our Investors Relations Contact below:

TOPADUR PHARMA AG
Markus Ducrey
Finance | Strategy
Grabenstrasse 11A
8952 Schlieren
SWITZERLAND

T: 41 44 755 44 61
investors@topadur.com